Point/Counterpoint: Quality of Life Considerations for Patients with Muscle Invasive Bladder Cancer Pro Trimodality Therapy

Similar documents
Bladder Preservation Strategies for Muscle Invasive Bladder Cancer

Trimodality Therapy for Muscle Invasive Bladder Cancer

Collection of Recorded Radiotherapy Seminars

Bladder Sparing Treatment of Muscle Invasive Bladder Cancer

Old and New Radiation for Bladder and Upper Tract Cancers. Bridget Koontz Radiation Oncology Duke Cancer Institute

Cochrane metaanalysis 5 year OS Intent to treat

Some Seminal Studies. Chemotherapy Alone is Inadequate. Bladder Cancer Role of Radiation in Bladder Sparing. Primary Radiation for Bladder Cancer

Nikapota AD 1*, Cresswell J 2, Appleyard, S 3, Catt SL 4.

High Risk Localized Prostate Cancer Treatment Should Start with RT

Breast cancer Can I still keep my breast?

Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline

Dr. Tareq Salah Ahmed,MD,ESMO. Lecturer of clinical oncology, Assiut faculty of medicine ESMO accreditation certificate

CHEMO-RADIOTHERAPY FOR BLADDER CANCER. Dr Darren Mitchell Consultant Clinical Oncologist Northern Ireland Cancer Centre

Alicia K. Morgans, MD Assistant Professor of Medicine Division of Hematology/Oncology Vanderbilt University Medical Center January 24, 2015

Neoadjuvant vs. Adjuvant Chemotherapy for Muscle-Invasive Bladder Cancer

Department of Urology, Cochin hospital Paris Descartes University

Cystectomies and bladder preservation: What you need to know

Does RT favor RP in long term Quality of Life? Juanita Crook MD FRCPC Professor of Radiation Oncology University of British Columbia

External Beam Radiation Therapy for Low/Intermediate Risk Prostate Cancer

Modern Dose Fractionation and Treatment Techniques for Definitive Prostate RT

Bladder replacement in men and women: when and when not? Outline. Continent Diversion History

Debate: Whole pelvic RT for high risk prostate cancer??

Bladder Cancer. Clinical Case Conference

Highlighting Clinical Trials Muscle Invasive Bladder Cancer

Early radical cystectomy in NMIBC Marko Babjuk

Salvage HDR Brachytherapy. Amit Bahl Consultant Clinical Oncologist The Bristol Cancer Institute, UK

ROBOTIC VS OPEN RADICAL CYSTECTOMY

The Rise, Fall, and Rise Again of Proton Therapy or Never count out a well-financed therapy

Locally advanced disease & challenges in management

PORT after RP. Adjuvant. Salvage

Case 1. Receives induction BCG weekly x 6 without significant toxicity Next step should be:

Partial Cystectomy for Invasive Bladder Cancer

Running head: Treatment modality and long term renal function in MIBC-Hamidi et al.

Chemo-radiotherapy in muscle invasive bladder cancer. Dr Paula Wells St Bartholomew s Hospital London

Patient Reported Outcomes and Building a Career in Science

Bladder Preservation Protocols in the Treatment of Muscle-Invasive Bladder Cancer

Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease

Recovery of sexual function after radical cystectomy with orthotopic neobladder

Risk of in-hospital complications after radical cystectomy for urinary bladder carcinoma: population-based follow-up study of 7608 patients

September 10, Dear Dr. Clark,

Complications in robotic surgery!! Review of the literature! RALP, RAPN and RARC!

Subject Index. Androgen antiandrogen therapy, see Hormone ablation therapy, prostate cancer synthesis and metabolism 49

AUA Guidelines for Invasive Bladder Cancer: What s New?

Eiji Kikuchi, Yutaka Horiguchi, Jun Nakashima, Takashi Ohigashi, Mototsugu Oya, Ken Nakagawa, Akira Miyajima and Masaru Murai

Adjuvant and Salvage Radiation for Prostate Cancer. Savita Dandapani, MD, PhD

2/14/09. Why Discuss this topic? Managing Local Recurrences after Radiation Failure. PROSTATE CANCER Second Treatment

CyberKnife SBRT for Prostate Cancer

Efficacy of Bladder-Preserving Therapy for Patients with T3b, T4a, and T4b Transitional Cell Carcinoma of the Bladder

Overview of Radiotherapy for Clinically Localized Prostate Cancer

Clinical Commissioning Policy Proposition: Robotic Assisted Surgery for Bladder Cancer

10th anniversary of 1st validated CaPspecific

Bladder Preservation for muscle invasive disease. Nicholas

THE ROLE OF RADIATION THERAPY IN MANAGEMENT OF PANCREATIC ADENOCARCINOMA. TIMUR MITIN, MD, PhD

SRO Tutorial: Prostate Cancer Clinics

When to Integrate Surgery for Metatstatic Urothelial Cancers

Radiation Therapy for Soft Tissue Sarcomas

Treatment of Invasive Bladder Cancer in the Elderly and Frail Pa9ent

Gynecologic Cancer InterGroup Cervix Cancer Research Network. The SHAPE Trial

Long-Term Complications of Conduit Urinary Diversion

The Rationale for Immunotherapy as an Adjuvant Treatment for Locally Advanced BC

The outcome of non-muscle invasive urinary bladder tumour at Makassed General Hospital

Body Image Following Radical Cystectomy and Ileal Neobladder or Conduit in Korean Patients

Urinary Adverse Events after Radiation Therapy for Prostate Cancer

Urinary Bladder Cancer

Future Directions in Prostate Cancer: The Case for Protons. John J. Coen, MD Helen & Harry Gray Cancer Center

Impact of invasive bladder cancer and orthotopic urinary diversion on general health-related quality of life: An SF-36 survey

Prostate cancer. Treatments Side effects and management in the community setting

Sexuality Preserving Cystectomy and Neobladder (SPCN): Functional Results of a Neobladder Anastomosed to the Prostate

Bladder-Sparing Treatment of Invasive Bladder Cancer

2018 ASTRO Refresher Course: Prostate Cancer. Timur Mitin, MD PhD Oregon Health and Science University

Incidental Dose to Pelvic Nodes in Bladder- Only Radiotherapy: Is It Clinically Relevant?

Surgical Management of Metastatic and Locally Recurrent Kidney Cancer: Does it Make Sense?

Patient Reported Outcomes After Radical Cystectomy

MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER

Pelvic palliative radiotherapy for gynecological cancers present state of knowledge and pending research questions to answer

Disclosures. Proton therapy advantages. Why are comparing therapies difficult? Proton Therapy for Low Risk Prostate Cancer

INFORMATION AND SUPPORTIVE CARE NEEDS OF INDIVIDUALS WITH BLADDER CANCER

Alleinige Radiochirurgie und alleinige Systemtherapie zwei «extreme» Entwicklungen in der Behandlung von Hirnmetastasen?

Palliative Care in Patients with Brain Tumors: How to maintain hope and quality of life, even when treatments fail

The quality of life in men after radical cystectomy with a continent cutaneous diversion or orthotopic bladder substitution: is there a difference?

2014 Best Papers in Robotic Cystectomy

How can we Personalize RT as part of Breast-Conserving Therapy?

Outlet Obliteration: In search of Drano

Can bladder preservation therapy come to the center stage?

Chemotherapy Treatment Algorithms for Urology Cancer

Gastroesophag Gastroesopha eal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. G. H addock Haddock M.D.

1. CyberKnife Centers of San Diego, CA 2. Coast Urology La Jolla, CA 3. Sletten Cancer Center Great Falls, MT

Part II: Treatment. A Woman-to-Woman Talk with Dr. Armine Smith. Wednesday, March 8, Presented by

S L I D E 0 S L I D E 1 S L I D E 2

URINARY DIVERSIONS. Susan Hilton, MD and Nicholas Papanicolaou, MD Co-Chiefs, CT Section Hospital of the University of Pennsylvania

Role of Belly Board Device in the Age of Intensity Modulated Radiotherapy for Pelvic Irradiation

Presentation, management, and outcomes of complications following prostate cancer therapy

1. Introduction. 2. Methods. high-risk NMIBC in men with and without a prior history of RT for PC.

Quality of life issues after treatment for prostate cancer

Irreversible Electroporation for the Treatment of Recurrent Prostate Cancer

INTRAOPERATIVE RADIATION THERAPY FOR RETROPERITONEAL SARCOMA

Curie - davinci connection

Understanding Women's Sexuality after Bladder Cancer webinar. Part I: The Physical Impact

Chemotherapy and Bladder Cancer. Blayne Welk UBC Urology Grand Rounds June 4, 2008

Transcription:

Point/Counterpoint: Quality of Life Considerations for Patients with Muscle Invasive Bladder Cancer Pro Trimodality Therapy Kimberley S. Mak, MD, MPH Assistant Professor Boston Medical Center Boston University School of Medicine

QOL Studies after Bladder-Sparing Trimodality Therapy (TMT)* *Bladder tumor resection and chemoradiation

TMT Clinical Trials RTOG trials: 157 patients treated with TMT who survived 2-13 years (median follow-up 5.2 years) Late Pelvic Toxicity Grade 1 22% Grade 2 10% Grade 3 Grade 4 0% Grade 5 0% 7.6% (5.7% GU, 1.9% GI) BC2001: 360 patients treated with radiation vs. TMT Grade 3-4 late toxicity: GU 3.3%; GI 0.8% Efstathiou JA, et al. JCO 2009 James ND, et al. NEJM 2012

MGH Urodynamics and QOL Study 221 patients treated with TMT on protocols 1986-2000, median follow-up 6.3 years 78% have compliant bladders with normal capacity and flow parameters 85% have no or occasional urgency 25% have occasional to moderate bowel control symptoms 50% of men have normal erectile function Zietman AL, et al. J Urol 2003

GETUG 97-015 Prospective Phase II study of 51 MIBC patients treated with TMT 1999-2001, without disease relapse, median follow-up 8 years Mean global QOL, physical, emotional, personal, cognitive, and social function scores >70% 100% satisfactory bladder function 70% maintained bladder function scores 1 year after treatment 79% had sexual activity 18 months after treatment (vs. 56% pre-treatment) Lagrange JL, et al. IJROBP 2011

Comparing Quality of Life after Surgery vs. Trimodality Therapy Little data comparing quality of life (QOL) after radical cystectomy (RC) vs. TMT 1 Randomized trial comparing RC to TMT (SPARE) closed early due to poor accrual 2 Both treatments have long-term effects on overall QOL, urinary, bowel, and sexual function, and selfimage 3 1. Lagrange JL, et al. IJROBP 2011 2. Huddart RA, et al. BJU Int 2010 3. Porter MP, et al. J Urol 2005

Cystectomy vs. Radiation Cross-sectional study from Karolinska Institute, Sweden 251 patients treated with cystectomy (incontinent and continent diversions) 58 patients treated with radiation 310 control individuals from general population Urinary function After radiation: 74% had no or little urinary symptom distress Bowel function After radiation: 32% had moderate or much bowel distress After cystectomy: 24% Control group: 9% Sexual function After radiation: 38% had intercourse in last month After cystectomy: 13% Henningsohn L, et al. Radiother Oncol 2002

Review of TMT QOL Studies Systematic review of 6 QOL studies after TMT (2 prospective, 4 retrospective) TMT associated with: Good general QOL compared to cystectomy Satisfactory urinary function Likely more bowel symptoms than cystectomy Satisfactory sexual function Included studies were limited by sample size, variable follow-up, and non-validated instruments Feuerstein MA, et al. Curr Urol Rep 2015

MGH/UNC: Long-Term QOL Cross-sectional study of 173 patients diagnosed in 1990-2011, disease-free for 2 years Treated at high-volume, academic medical centers with modern techniques Median follow-up: 5.6 years - 63% patients received cystectomy (n=109) - 82% ileal conduit and 18% neobladder diversions - 37% received TMT (n=64 ) - 9% required salvage cystectomy (n=6) Six validated QOL questionnaires, scored out of 100 Mak KS, Smith AS et al. ASCO GU 2015, ASTRO 2015, under review at IJROBP

MGH/UNC: Long-Term QOL Both cystectomy and TMT associated with good long-term QOL outcomes Compared to RC, TMT associated with: Modestly higher general QOL (by 7-10 points) Similar urinary scores Modestly higher bowel function (by 3-7 points) Markedly better sexual QOL (by 9-32 points) Better informed decision-making (by 14 points) Less concerns about appearance (by 14 points) Less life interference from cancer or cancer treatment (by 9 points)

What about TMT patients who needed salvage cystectomy? 91 patients at MGH who underwent salvage cystectomy for persistent disease (n=50) or recurrent disease (n=41)* Clavien Scale Complication w/in 90 days of Surgery Salvage Cystectomy Grade 1 45% 26% Grade 2 38% 62% Grade 3 14% 11% Grade 4 2% 0% Grade 5 2% 2% Radical Cystectomy (MSKCC series of 1142 patients) * No patients required cystectomy due to treatment toxicity in MGH experience or on RTOG protocols Eswara JR, et al. J Urol 2012 Ploussard G, et al. Eur Urol 2014

Does TMT offer better QOL than Cystectomy? Sexual function Adjustment to appearance and life interference Informed decisionmaking General QOL? Urinary function General QOL? Bowel function? Bowel function?

Conclusions Both cystectomy and TMT can be used to treat bladder cancer More prospective studies are needed to evaluate outcomes (including QOL) after each treatment

Thank you! The best bladder you will ever have is the one you are born with (even after bladder tumor resection and chemoradiation) - Anthony Zietman, MD